[go: up one dir, main page]

SG11202008345RA - Fecal matter for prevention or treatment of autoimmune diseases - Google Patents

Fecal matter for prevention or treatment of autoimmune diseases

Info

Publication number
SG11202008345RA
SG11202008345RA SG11202008345RA SG11202008345RA SG11202008345RA SG 11202008345R A SG11202008345R A SG 11202008345RA SG 11202008345R A SG11202008345R A SG 11202008345RA SG 11202008345R A SG11202008345R A SG 11202008345RA SG 11202008345R A SG11202008345R A SG 11202008345RA
Authority
SG
Singapore
Prior art keywords
prevention
treatment
autoimmune diseases
fecal matter
fecal
Prior art date
Application number
SG11202008345RA
Inventor
Max Nieuwdorp
Vos Willem Meindert De
Original Assignee
Acad Medisch Ct
Univ Wageningen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NL2021365A external-priority patent/NL2021365B1/en
Application filed by Acad Medisch Ct, Univ Wageningen filed Critical Acad Medisch Ct
Publication of SG11202008345RA publication Critical patent/SG11202008345RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37Digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37Digestive system
    • A61K35/38Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202008345RA 2018-03-02 2019-03-01 Fecal matter for prevention or treatment of autoimmune diseases SG11202008345RA (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
NL2020525 2018-03-02
NL2021365A NL2021365B1 (en) 2018-07-20 2018-07-20 Fecal matter for prevention or treatment of autoimmune diseases
NL2021370 2018-07-20
NL2021366 2018-07-20
NL2021369 2018-07-20
NL2021367 2018-07-20
PCT/NL2019/050130 WO2019168401A1 (en) 2018-03-02 2019-03-01 Fecal matter for prevention or treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
SG11202008345RA true SG11202008345RA (en) 2020-09-29

Family

ID=66290492

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008345RA SG11202008345RA (en) 2018-03-02 2019-03-01 Fecal matter for prevention or treatment of autoimmune diseases

Country Status (12)

Country Link
US (1) US11534465B2 (en)
EP (1) EP3758721B1 (en)
JP (1) JP7175990B2 (en)
KR (1) KR20200128126A (en)
CN (1) CN111936154A (en)
AU (1) AU2019229090A1 (en)
BR (1) BR112020016771A2 (en)
CA (1) CA3091916A1 (en)
ES (1) ES2924041T3 (en)
RU (1) RU2020131222A (en)
SG (1) SG11202008345RA (en)
WO (1) WO2019168401A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2025022B1 (en) 2020-02-28 2021-10-14 Acad Medisch Ct Intervention strategy for prevention or treatment of autoimmune diseases
AU2021228209A1 (en) * 2020-02-28 2022-08-11 Stichting Amsterdam UMC Intervention strategy for prevention or treatment of Diabetes mellitus, autoimmune disease, inflammatory disease or cardiovascular disease
NL2025021B1 (en) 2020-02-28 2021-10-14 Univ Wageningen Intervention strategy for prevention or treatment of autoimmune diseases
NL2025020B1 (en) 2020-02-28 2021-10-14 Acad Medisch Ct Intervention strategy for prevention or treatment of autoimmune diseases
EP4183403A1 (en) * 2021-11-19 2023-05-24 Lietuvos Sveikatos Mokslu Universitetas Modification of fecal microbiota with capsules containing gram-positive bacteria
CN114196543A (en) * 2021-11-25 2022-03-18 天津大学浙江绍兴研究院 A fecal bacteria cryoprotectant and its application in the preservation of fecal bacteria

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9463174B2 (en) * 2008-12-19 2016-10-11 Qinghua Wang Pharmaceutical composition for the treatment of type-1 diabetes
PH12013500224A1 (en) 2010-08-04 2013-04-08 Borody Thomas J Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
DK2753187T3 (en) * 2011-08-30 2019-01-28 Caelus Pharmaceuticals B V Method of preventing and / or treating insulin resistance
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
WO2016070151A1 (en) * 2014-10-31 2016-05-06 Whole Biome. Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
FR3045383B1 (en) * 2015-12-18 2019-06-14 Maat Pharma PROCESS FOR THE FREEZING OF A FECAL MICROBIOTE SAMPLE

Also Published As

Publication number Publication date
EP3758721A1 (en) 2021-01-06
JP2021514950A (en) 2021-06-17
US11534465B2 (en) 2022-12-27
CA3091916A1 (en) 2019-09-06
CN111936154A (en) 2020-11-13
BR112020016771A2 (en) 2020-12-15
RU2020131222A (en) 2022-04-06
JP7175990B2 (en) 2022-11-21
KR20200128126A (en) 2020-11-11
ES2924041T3 (en) 2022-10-04
US20210137994A1 (en) 2021-05-13
AU2019229090A1 (en) 2020-10-08
WO2019168401A1 (en) 2019-09-06
EP3758721B1 (en) 2022-05-18

Similar Documents

Publication Publication Date Title
SG11202008345RA (en) Fecal matter for prevention or treatment of autoimmune diseases
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
ZA202006610B (en) Compositions for the treatment of skin conditions
IL279260A (en) Kdm1a inhibitors for the treatment of disease
ZA202007055B (en) Compositions for the treatment of skin conditions
GB201804514D0 (en) Treatment of pyroptosis
ZA202108219B (en) Combination treatment of arthritic disease
PL3612208T3 (en) Coversin for the treatment of autoimmune blistering diseases
IL272937A (en) Compositions and methods for the treatment of fibrotic diseases
ZA202006234B (en) Compositions and methods for the treatment of neurological diseases
GB201805100D0 (en) Treatment of sarcopenic diseases
ZA201903795B (en) Treatment of water
GB201804515D0 (en) Treatment of necroptosis
IL282360A (en) Treatment of neurological diseases
GB201522329D0 (en) Use of adjuvants for the prevention and/or treatment of autoimmune diseases
GB201907305D0 (en) Treatment of conditions
IL261779A (en) Compositions for the treatment and prevention of hoof and claw diseases
GB201806663D0 (en) 2-Oxothiazole compositions for treatment of fibrotic disease
IL278845A (en) Inhibition of neurological disease
PT3752173T (en) Combination of rhodiola and astragalus for the treatment of neurodegenerative diseases
GB201811375D0 (en) Treatment of autoimmune disease
GB2603379B (en) Avocatin B for the treatment of diseases and conditions
GB201811911D0 (en) Treatment of disease
GB201811912D0 (en) Treatment of disease
GB201810974D0 (en) Treatment of disease